36th Annual J.P. Morgan Healthcare Conference Marc N. Casper - - PowerPoint PPT Presentation

36th annual j p morgan healthcare conference
SMART_READER_LITE
LIVE PREVIEW

36th Annual J.P. Morgan Healthcare Conference Marc N. Casper - - PowerPoint PPT Presentation

36th Annual J.P. Morgan Healthcare Conference Marc N. Casper President and Chief Executive Officer January 9, 2018 The world leader in serving science Safe Harbor / Non-GAAP Measures Various remarks that we may make in the following


slide-1
SLIDE 1

The world leader in serving science

Marc N. Casper President and Chief Executive Officer January 9, 2018

36th Annual J.P. Morgan Healthcare Conference

slide-2
SLIDE 2

2

Various remarks that we may make in the following presentation about the company’s future expectations, plans and prospects constitute forward- looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our Form 10- Q for the quarter ended September 30, 2017, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international

  • perations; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations

governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as

  • expected. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if

estimates change, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. During this presentation, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP, including adjusted EPS and adjusted operating margin. The non-GAAP financial measures of Thermo Fisher’s results of operations and cash flows included in this presentation are not meant to be considered superior to or a substitute for Thermo Fisher’s results of operations prepared in accordance with GAAP. Definitions of these non-GAAP financial measures and, for historical periods, a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available under the heading “GAAP/Non-GAAP Reconciliation & Financial Package” in the “Investors” section of our website, www.thermofisher.com.

Safe Harbor / Non-GAAP Measures

slide-3
SLIDE 3

3

Unmatched Depth

  • Leading innovative technologies
  • Deep applications expertise
  • Premier laboratory productivity partner
  • Leading pharma services provider

Our Mission: To enable our customers to make the world healthier, cleaner and safer

We Are The World Leader in Serving Science

Global Scale

  • Approximately 65,000 employees globally
  • $20 billion in annual revenue
  • Unparalleled commercial reach
slide-4
SLIDE 4

4

Attractive Revenue Profile Positions Us for Growth

Balanced and Diverse Customer Base Growing Presence in Emerging Markets Strong Recurring Revenue Mix

NOTE: Pro forma revenue and percentages based on LTM through Q3 2017.

Total Pro Forma Revenue Including Patheon: ~$22B

Industrial & Applied

20%

Diagnostics & Healthcare

21%

Pharma & Biotech

36%

Academic & Government

23%

Consumables

53%

Services

22%

Instruments

25%

Europe

24%

Asia-Pacific

21%

ROW

3%

52%

North America

slide-5
SLIDE 5

5

Complementary Segments Create Competitive Advantage

Analytical Instruments

Revenue: $4.6B Adj. Operating Income: 21.2%

Life Sciences Solutions

Revenue: $5.6B Adj. Operating Income: 32.4%

Laboratory Products and Services

Pro Forma Revenue: $8.8B Pro Forma Adj. Operating Income: 12.5%

Specialty Diagnostics

Revenue: $3.4B Adj. Operating Income: 26.9%

Microbiology

Antimicrobial Susceptibility Testing Solutions QuantStudio Dx R qPCR

Genetic Sciences Laboratory Chemicals Bioproduction

Cell Culture Reagents

Biosciences

Life Science Reagents

Mass Spectrometry

Fusion Lumos MS

Chromatography

Vanquish UHPLC

Electron Microscopy

Titan Krios TEM

Reproductive Health

Microarrays iCAP Triple Quad MS

Clinical Diagnostics

PCT Biomarkers

Lab Equipment & Consumables

TSX ULT Freezers

ImmunoDiagnostics

ImmunoCAP Allergy and EliA Autoimmunity Tests

NOTE: Revenue and Adjusted Operating Income Margins are based on LTM through Q3 2017. Revenue and Adjusted Operating Income Margin for Laboratory Products and Services are calculated on a Pro Forma basis which includes the pre-acquisition results of Patheon for the entire period

SeqStudio CE System E1 ClipTip Pipette System

Clinical Oncology

Next-Gen Sequencing

Transplant Diagnostics

NXType High-Resolution Genotyping

Chemical Analysis

Gemini Handheld Analyzer

Channel BioPharma Services

Cryostar Tissue Sectioning

Pathology

slide-6
SLIDE 6

6

Consistently Delivering Excellent Financial Performance

2012 2016 2012 2016

9% CAGR 14% CAGR

Adjusted EPS Revenue Leveraging our industry leadership to achieve outstanding results

12% CAGR

Free Cash Flow

2011 Q3 2017 LTM 2011 2011 Q3 2017 LTM Q3 2017 LTM

slide-7
SLIDE 7

7

2017 Goals (as communicated at JPM Conference on January 10, 2017)

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Leverage our expansive commercial capabilities to capture the most significant opportunities within our key end-markets
  • Margin
  • Drive cost management initiatives through global sourcing programs, low-cost region expansion, footprint optimization, and our

PPI business system

  • Take actions to reduce the adverse impact of FX and higher interest rates on variable rate debt
  • Capture Synergies from Affymetrix and FEI Acquisitions
  • Capital Deployment
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, dividends, and debt repayment
  • ROIC
  • Keep momentum on driving returns from our acquisitions and other investments
slide-8
SLIDE 8

8

2017 Goals (as communicated at JPM Conference on January 10, 2017)

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Leverage our expansive commercial capabilities to capture the most significant opportunities within our key end-markets
  • Margin
  • Drive cost management initiatives through global sourcing programs, low-cost region expansion, footprint optimization, and our

PPI business system

  • Take actions to reduce the adverse impact of FX and higher interest rates on variable rate debt
  • Capture Synergies from Affymetrix and FEI Acquisitions
  • Capital Deployment
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, dividends, and debt repayment
  • ROIC
  • Keep momentum on driving returns from our acquisitions and other investments
slide-9
SLIDE 9

9

2017: Another Excellent Year of High Impact Innovation

  • Greater understanding of protein

structure and function

  • Leading cryo-electron microscopy and high-

resolution mass spectrometry platforms

  • Applying precision medicine approach

in the real world

  • Unique portfolio spanning genetic and

protein analysis, biobanking, informatics and diagnostics

  • Sample-to-answer solutions
  • Integrated chromatography and mass

spectrometry workflows combining instruments, software and consumables

  • More accurate and cost-effective

diagnostics

  • Developing mass spectrometry-based

patient sample-to-answer clinical analyzer

  • Effective data management and analytics
  • Comprehensive digital science capabilities

Industry-leading R&D Investment

Customer Needs Our Solutions

Innovation investments put us at the forefront of scientific advances

6.6% of Total Manufacturing Revenue

$0.9B

NOTE: R&D and revenue based on LTM through Q3 2017.

slide-10
SLIDE 10

10

  • Greater understanding of protein

structure and function

  • Leading cryo-electron microscopy and high-

resolution mass spectrometry platforms

  • Applying precision medicine approach

in the real world

  • Unique portfolio spanning genetic and

protein analysis, biobanking, informatics and diagnostics

  • Sample-to-answer solutions
  • Integrated chromatography and mass

spectrometry workflows combining instruments, software and consumables

  • More accurate and cost-effective

diagnostics

  • Developing mass spectrometry-based

patient sample-to-answer clinical analyzer

  • Effective data management and analytics
  • Comprehensive digital science capabilities

Industry-leading R&D Investment

Customer Needs Our Solutions

Innovation investments put us at the forefront of scientific advances

6.6% of Total Manufacturing Revenue

$0.9B

NOTE: R&D and revenue based on LTM through Q3 2017.

SeqStudio Genetic Analyzer Oncomine Dx Target Test Q Exactive HF-X Quadrupole-Orbitrap mass spectrometer ClipTip cloud-connected electronic pipette system

2017 Product Introduction Highlights

2017: Another Excellent Year of High Impact Innovation

Krios G3i Cryo-TEM

slide-11
SLIDE 11

11

China Market Dynamics $19.8B

Revenue

China

10%

Developed Markets

79%

Emerging Markets account for 21% of revenue

Capitalizing on attractive fundamentals and continuing to gain share

3

NOTE: Revenue and geographic percentages in pie chart based on LTM through Q3 2017.

Scale in Emerging Markets: China Example

Other Emerging Markets

11%

2011 2016 LTM Q3 2017

$0.6B $1.7B $2.0B

Thermo Fisher China Revenue

  • Attractive fundamentals
  • $9B market growing at 9% CAGR
  • 13th 5-Year Plan focused on

innovation, healthcare and precision medicine, environment and food safety

  • 2017 progress:
  • Opened Precision Medicine

Customer Experience Center in Guangzhou, China

  • Increased manufacturing revenue

by over 10% to support growing local and global demand

  • Grew e-business sales by over 50%

16%

Average

  • rganic

growth

slide-12
SLIDE 12

12

2017 Goals (as communicated at JPM Conference on January 10, 2017)

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Leverage our expansive commercial capabilities to capture the most significant opportunities within our key end-markets
  • Margin
  • Drive cost management initiatives through global sourcing programs, low-cost region expansion, footprint optimization, and our

PPI business system

  • Take actions to reduce the adverse impact of FX and higher interest rates on variable rate debt
  • Capture Synergies from Affymetrix and FEI Acquisitions
  • Capital Deployment
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, dividends, and debt repayment
  • ROIC
  • Keep momentum on driving returns from our acquisitions and other investments
slide-13
SLIDE 13

13

Quality Productivity Customer Allegiance

Consistently deliver world-class products and services Exceed expectations to maximize customer success Improve operating and process efficiency to strengthen

  • ur competitive

advantage

  • Accelerate organic growth
  • Expand margins
  • Enhance cash flow

Impact of PPI:

Practical Process Improvement (PPI) Business System Drives Operational Excellence

Adjusted Operating Margin %

2011 Q3 2017 LTM

23.4% 18.4%

slide-14
SLIDE 14

14

2017 Goals (as communicated at JPM Conference on January 10, 2017)

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Leverage our expansive commercial capabilities to capture the most significant opportunities within our key end-markets
  • Margin
  • Drive cost management initiatives through global sourcing programs, low-cost region expansion, footprint optimization, and our

PPI business system

  • Take actions to reduce the adverse impact of FX and higher interest rates on variable rate debt
  • Capture Synergies from Affymetrix and FEI Acquisitions
  • Capital Deployment
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, dividends, and debt repayment
  • ROIC
  • Keep momentum on driving returns from our acquisitions and other investments
slide-15
SLIDE 15

15

Affymetrix & FEI: On Track to Meet or Exceed Deal Expectations FEI

(acquired September 2016)

  • Organic growth accelerated from low single-digits

to strong double-digits

  • On track to exceed total synergy target of $80M by

Year 3 (2019):

  • PPI Business System has dramatically increased

manufacturing capacity which has helped capture incremental growth

  • ROIC hurdle expected one year earlier

versus original deal model

Affymetrix

(acquired March 2016)

  • Good growth in 2017 driven by new product

introductions and leveraging our commercial reach

  • On track to exceed total synergy target of $70M by

Year 3 (2019):

  • Strong contribution from PPI Business System
  • Consolidate business infrastructure into our organization
  • On track to achieve deal model
slide-16
SLIDE 16

16

2017 Goals (as communicated at JPM Conference on January 10, 2017)

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Leverage our expansive commercial capabilities to capture the most significant opportunities within our key end-markets
  • Margin
  • Drive cost management initiatives through global sourcing programs, low-cost region expansion, footprint optimization, and our

PPI business system

  • Take actions to reduce the adverse impact of FX and higher interest rates on variable rate debt
  • Capture Synergies from Affymetrix and FEI Acquisitions
  • Capital Deployment
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, dividends, and debt repayment
  • ROIC
  • Keep momentum on driving returns from our acquisitions and other investments
slide-17
SLIDE 17

17

2017 Capital Deployment Summary

  • $750M in Share Buybacks
  • $240M in Dividends
  • $7.8B in M&A
  • $7.4B for Patheon ($5.7 Debt/ $1.7B Equity)
  • $0.4B for Finesse Solutions, Core Informatics, Linkage Biosciences and Phenom World
slide-18
SLIDE 18

18

Patheon Overview

  • St. Louis, MO

Manati, Puerto Rico Florence, SC Greenville, NC Linz, Austria Ferentino and Monza, Italy

Locations

Drug Substance Services - Biologics Drug Substance Services - API Drug Product Services Pharma Development Services

4%

28% 68%

Europe North America ROW

Revenue by Geography

12% 27%

Revenue by Business / Capability

61%

Pharmaceutical Development Services

  • Leading global provider of CDMO services
  • Revenue: $1.9B
  • Adjusted operating margin of 17%
  • ~9,000 employees globally
  • 26 manufacturing and development locations

Drug Substance Services

Serves API Manufacturing Segment

Drug Product Services

Serves Finished Dosage Form Manufacturing Segment

Note: Financials reflect LTM as of Jan 31, 2017

slide-19
SLIDE 19

19

2017 Goals (as communicated at JPM Conference on January 10, 2017)

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Leverage our expansive commercial capabilities to capture the most significant opportunities within our key end-markets
  • Margin
  • Drive cost management initiatives through global sourcing programs, low-cost region expansion, footprint optimization, and our

PPI business system

  • Take actions to reduce the adverse impact of FX and higher interest rates on variable rate debt
  • Capture Synergies from Affymetrix and FEI Acquisitions
  • Capital Deployment
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, dividends, and debt repayment
  • ROIC
  • Keep momentum on driving returns from our acquisitions and other investments
slide-20
SLIDE 20

20

Improving Adjusted ROIC

Note: Adjusted return on invested capital is annual adjusted net income excluding net interest expense, net of tax benefit therefrom, divided by trailing five quarters average invested capital.

Adjusted ROIC

10.7%

(w/o M&A)

9.8% 9.8%

Q3 2017 Q3 2016

  • Expanding adjusted ROIC by 90-120 bps

annually on an operational basis Capital Deployed on M&A:

  • FY 2016: $5.5B (e.g., FEI and Affymetrix)
  • FY 2017: $7.8B (e.g., Patheon)
slide-21
SLIDE 21

21

2017 Goals (as communicated at JPM Conference on January 10, 2017)

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Leverage our expansive commercial capabilities to capture the most significant opportunities within our key end-markets
  • Margin
  • Drive cost management initiatives through global sourcing programs, low-cost region expansion, footprint optimization, and our

PPI business system

  • Take actions to reduce the adverse impact of FX and higher interest rates on variable rate debt
  • Capture Synergies from Affymetrix and FEI Acquisitions
  • Capital Deployment
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, dividends, and debt repayment
  • ROIC
  • Keep momentum on driving returns from our acquisitions and other investments

Successfully achieved key business goals & delivered solid returns

slide-22
SLIDE 22

22

2018 Goals

  • Revenue
  • Continue to launch high-impact new products
  • Leverage our unique customer value proposition by cross selling our total portfolio
  • Capture further share gain opportunities in emerging markets by continuing to leverage our commercial reach
  • Margins/Below the Line
  • Leverage PPI business system throughout organization to reduce cost and enhance productivity
  • Take full advantage of U.S. tax reform to reduce total company tax rate
  • Patheon: Successfully integrate, drive growth and capture synergies
  • Capital Deployment
  • Keep momentum on driving returns from our acquisitions and other investments
  • Continue shareholder friendly capital deployment through strategic M&A, share buybacks, and dividends,

while continuing debt repayment